Nanobiotix (0QAV) Price & Analysis

Compare

4 Followers

0QAV Stock Chart & Stats

€22.35

-€0.07(-2.36%)

At close: Jan 09 4:00 PM EST

€22.35

-€0.07(-2.36%)

Day’s Range― - ―

52-Week Range€2.68 - €25.55

Previous CloseN/A

Volume19.00

Average Volume (3M)47.85K

Market Cap

€1.07B

Enterprise Value€218.02M

Total Cash (Recent Filing)€49.74M

Total Debt (Recent Filing)€50.90M

Price to Earnings (P/E)―

Beta2.12

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Mar 15, 2022

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding47,943,150

10 Day Avg. Volume62,181

30 Day Avg. Volume47,854

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-2.17

Price to Sales (P/S)-12.30

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€22.00

Price Target Upside-1.57% Downside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical DataNanobiotix presented clinical data updates showing JNJ-1900 can elicit anti-tumor activity both locally at the injected lesion and systemically.

Earnings PotentialNanobiotix is eligible to receive tiered royalties and medium-term milestones, including significant payments if certain data milestones are positive.

EfficacyLocal efficacy and overall safety strengthen the case for JNJ-1900 combinability, with strong overall efficacy suggesting a potential association between local response and improved response when combined with systemic treatment.

Bears Say

Development ChallengesThe need for further evaluations in more advanced clinical trials indicates potential challenges in proving JNJ-1900's efficacy across diverse cancer types.

Nanobiotix News

Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 20 from EUR 13 and keeps...

18d ago

NBTX

Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts

Nanobiotix (NBTX) announced first data from cohorts 1 and 2 of the dose escalation part of a Phase...

18d ago

JNJ

NBTX

Nanobiotix price target raised to EUR 13 from EUR 10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 13 from EUR 10 and keeps...

1M ago

NBTX

Nanobiotix price target raised to $14 from $9 at Leerink

Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $14 from $9 and keeps...

1M ago

NBTX

Nanobiotix announces new results from JNJ-1900 study

Nanobiotix (NBTX) announced new results focused on patients with primary cutaneous melanoma from the ongoing Phase 1 Study...

1M ago

JNJ

NBTX

Nanobiotix SA – ADR trading resumes

09:35 EDT Nanobiotix (NBTX) SA – ADR trading resumes Published first on TheFly – the ultimate source for...

3M ago

NBTX

Nanobiotix SA – ADR trading halted, volatility trading pause

09:30 EDT Nanobiotix (NBTX) SA – ADR trading halted, volatility trading pause Published first on TheFly – the...

3M ago

NBTX

Nanobiotix announces regulatory harmonization, new patent for JNJ-1900

Nanobiotix (NBTX) announced two developments related to radioenhancer JNJ-1900, which is licensed by Janssen Pharmaceutica, a Johnson &...

3M ago

JNJ

NBTX

Promising Clinical Developments and Strategic Partnerships Propel Nanobiotix to a Buy Rating

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Nanobiotix (0QAV – Research Report), retaining the...

5M ago

NBTX

Nanobiotix’s Strategic Advancements and Financial Strength Bolster Buy Rating

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Nanobiotix (NBTX – Research Report) yesterday and set...

5M ago

NBTX

Nanobiotix’s NBTXR3: Promising Survival Benefits and Strategic Collaborations Justify Buy Rating

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix (0QAV – Research Report) and keeping...

6M ago

NBTX

Nanobiotix SA’s Positive Earnings Call Highlights Strategic Growth

Nanobiotix SA (($FR:NANO)) has held its Q4 earnings call. Read on for the main highlights of the call....

7M ago

Nanobiotix price target lowered to $8 from $12 at Guggenheim

Guggenheim lowered the firm’s price target on Nanobiotix (NBTX) to $8 from $12 and keeps a Buy rating...

7M ago

NBTX

Nanobiotix’s Promising Future: Buy Rating Backed by Data-Rich 2025 and Strategic Advancements

Nanobiotix (0QAV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

7M ago

NBTX

0QAV FAQ

What was Nanobiotix SA’s price range in the past 12 months?

Nanobiotix SA lowest share price was €2.68 and its highest was €25.55 in the past 12 months.

What is Nanobiotix SA’s market cap?

Nanobiotix SA’s market cap is €1.07B.

When is Nanobiotix SA’s upcoming earnings report date?

Nanobiotix SA’s upcoming earnings report date is Nov 18, 2025 which is in 29 days.

How were Nanobiotix SA’s earnings last quarter?

Nanobiotix SA released its earnings results on Sep 30, 2025. The company reported -€0.11 earnings per share for the quarter, beating the consensus estimate of -€0.31 by €0.2.

Is Nanobiotix SA overvalued?

According to Wall Street analysts Nanobiotix SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanobiotix SA pay dividends?

Nanobiotix SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Nanobiotix SA dividends here

What is Nanobiotix SA’s EPS estimate?

Nanobiotix SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanobiotix SA have?

Nanobiotix SA has 47,943,150 shares outstanding.

What happened to Nanobiotix SA’s price movement after its last earnings report?

Nanobiotix SA reported an EPS of -€0.11 in its last earnings report, beating expectations of -€0.31. Following the earnings report the stock price went down -3.929%.

Which hedge fund is a major shareholder of Nanobiotix SA?

Currently, no hedge funds are holding shares in GB:0QAV

Company Description

Nanobiotix SA

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix (0QAV) Earnings & Revenues

Historic Earnings Reports

0QAV Stock 12 Month Forecast

Average Price Target

€22.00

▼(-1.57% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","26":"€26","7.25":"€7.25","13.5":"€13.5","19.75":"€19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.14,16.821538461538463,17.503076923076925,18.184615384615384,18.866153846153846,19.54769230769231,20.22923076923077,20.910769230769233,21.592307692307692,22.273846153846154,22.955384615384617,23.636923076923075,24.31846153846154,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.14,16.590769230769233,17.04153846153846,17.492307692307694,17.943076923076923,18.393846153846155,18.844615384615384,19.295384615384616,19.746153846153845,20.196923076923078,20.647692307692306,21.09846153846154,21.549230769230768,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.14,16.436923076923076,16.733846153846155,17.03076923076923,17.32769230769231,17.624615384615385,17.92153846153846,18.21846153846154,18.515384615384615,18.81230769230769,19.10923076923077,19.406153846153845,19.703076923076924,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.71,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.97,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >